Skip to main content
    C

    Context Therapeutics Inc (CNTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.17
    -0.01 (-8.24%)

    Market Cap: $16.61M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Context Therapeutics Inc (CNTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Context Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$36.12M, operating cash flow was -$26.39M and free cash flow was -$26.42M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$7.62M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $39.70M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2017Dec 2016
    Research and development$31.86M$22.70M$17.78M$7.59M$6.89M$1.64M$2.41M$17.62M$27.79M
    Operating income-$39.70M-$29.92M-$25.07M-$15.38M-$10.53M-$2.57M-$5.38M-$24.05M-$33.23M
    Net income-$36.12M-$26.73M-$23.96M-$14.84M-$10.46M$6.64M-$7.48M-$24.61M-$37.67M
    EBITDA-$39.49M-$29.91MN/A-$15.37M-$10.52M$7.31M-$5.38MN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$0$0$0$0$18.95K
    Gross profit$0$0$0-$32.28K$0$0$0N/A$0$0$0$16.38K
    Operating income-$7.96M-$14.97M-$9.34M-$13.80M-$10.61M-$9.76M-$5.53M-$4.31M-$18.70M-$3.09M-$3.82M-$6.93M
    Net income-$7.62M-$14.56M-$8.68M-$13.03M-$9.69M-$8.83M-$4.58M-$3.34M-$17.46M-$2.25M-$3.67M-$6.77M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $112.06K by $65.88M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2017Dec 2016
    Total assets$68.49M$98.13M$16.06M$37.97M$51.31M$467.34K$273.55K$68.34M$24.01M
    Current assets$68.35M$97.90M$16.05M$37.85M$51.26M$299.34K$239.61K$61.34M$17.06M
    Cash and equivalents$66.00M$94.43M$14.45M$35.50M$49.64M$290.67K$226.60K$60.68M$16.23M
    Total liabilities$8.02M$2.86M$4.19M$3.21M$3.03M$9.62M$24.23M$9.38M$10.89M
    Short-term debt$112.06K$107.32KN/A$55.08KN/A$5.88M$21.84M$1.58M$1.58M
    Long-term debtN/AN/AN/AN/AN/A$69.04KN/A$390.00K$1.96M
    Shareholder equity$60.47M$95.27M$11.87M$34.76M$48.27M-$16.92M-$23.96M$58.95M$13.12M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$36.54M$46.13M$58.86M$68.49M$79.23M$87.15M$92.97M$98.13M$86.33M$102.71M$11.05M$16.06M
    Total liabilities$5.53M$7.96M$6.66M$8.02M$6.06M$4.61M$1.98M$2.86M$2.47M$1.60M$2.61M$4.19M
    Cash and equivalents$34.41M$42.99M$54.53M$66.00M$76.94M$83.52M$89.35M$94.43M$84.80M$101.54M$10.09M$14.45M
    Shareholder equity$31.01M$38.17M$52.20M$60.47M$73.17M$82.54M$90.98M$95.27M$83.86M$101.10M$8.44M$11.87M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2017Dec 2016
    Operating cash flow-$26.39M-$14.56M-$21.05M-$13.55M-$8.80M-$1.03M-$2.84M-$22.35M-$30.57M
    Capital expenditures$33.95K$7.32K$0$36.84K$0$0$0$28.00K$28.00K
    Free cash flow-$26.42M-$14.56M-$21.05M-$13.59M-$8.80M-$1.03M-$2.84M-$22.38M-$30.60M
    Share repurchases$15.27K$0N/A$102.07K$0N/AN/AN/AN/A
    Investing cash flow-$2.03M-$14.76M$0-$536.84K-$250.00K$0-$250.00K-$28.00K-$28.00K
    Financing cash flow-$15.27K$109.29M$0-$102.07K$58.39M$1.15M$1.96M$66.83M$44.18M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$6.58M-$7.02M-$11.43M-$8.94M-$6.58M-$5.84M-$5.03M-$4.91M-$1.93M-$3.36M-$4.36M-$7.23M
    Capital expendituresN/A$18.49K$37.26K$5$0$0$33.95K$0$7.32K$4$0$0
    Free cash flowN/A-$7.04M-$11.47M-$8.94M-$6.58M-$5.84M-$5.06M-$4.91M-$1.94M-$3.36M-$4.36M-$7.23M
    Last 12 quarters

    Frequently Asked Questions About CNTX

    What is Context Therapeutics' annual revenue?

    Context Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Context Therapeutics profitable?

    No. Context Therapeutics reported net income of -$36.12M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CNTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$26.39M minus capital expenditures of $33.95K produced free cash flow of -$26.42M.

    How much debt does Context Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $112.06K and cash and equivalents of $66.00M.